Therapeutic options for continuous dopaminergic stimulation in Parkinson's disease

Therapeutic Advances in Neurological Disorders

Volumn 2, Issue 2, 2009, Pages 105-113

  Sujith, O K ^a   Lane, Carol ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Continuous dopaminergic stimulation; Intraduodenal administration; Levodopa; Parkinsonism

Indexed keywords

APOMORPHINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LEVODOPA METHYL ESTER; LISURIDE; PLACEBO; ROPINIROLE; ROTIGOTINE;

BRAIN DEPTH STIMULATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY SPASM; DOPAMINERGIC TRANSMISSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; GENE CONTROL; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA; NERVE CELL; ORTHOSTATIC HYPERTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REGULATORY MECHANISM; REVIEW; SOMNOLENCE; SUSTAINED DRUG RELEASE;

EID: 77953391147     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285608101378     Document Type: Review

References (76)

1. Agid, Y. (1991) Parkinson's disease: pathophysiology, Lancet 337: 1321-1324.
2. Ahlskog, J.E. and Muenter, M.D. (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature, Mov Disord 16: 448-458.
3. Albin, R.L., Young, A.B. and Penney, J.B. (1995) The functional anatomy of disorders of the basal ganglia, Trends Neurosci 18: 63-64.
4. Antonini, A. (2007) Continuous dopaminergic stimulation - from theory to clinical practice, Parkinsonism Relat Disord 13(Suppl.): S24-S28.
5. Antonini, A., Isaias, I.U., Canesi, M., Zibetti, M., Mancini, F., Manfredi, L. et al. (2007) Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome, Mov Disord 22: 1145-1149.
6. Antonini, A., Mancini, F., Canesi, M., Zangaglia, R., Isaias, I.U., Manfredi, L. et al. (2008) Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease, Neurodegener Dis 5: 244-246.
7. Baldwin, C.M. and Keating, G.M. (2007) Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease, CNS Drugs 21: 1039-1055.
8. Ballard, P.A., Tetrud, J.W. and Langston, J.W. (1985) Permanent human parkinsonism due to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): seven cases, Neurology 35: 949-956.
9. Block, G., Liss, C., Reines, S., Irr, J. and Nibbelink, D. (1997) Comparison of immediate-release and controlled release carbidopa / levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group, Eur Neurol 37: 23-27.
10. Bredberg, E., Lennernas, H. and Paalzow, L. (1994) Pharmacokinetics of levodopa and carbidopa in rats following different routes of administration, Pharm Res 11: 549-555.
11. Calon, F., Morissette, M., Rajput, A.H., Hornykiewicz, O., Bedard, P.J. and Di Paolo, T. (2003 a) Changes of GABA receptors and dopamine turnover in the postmortem brains of parkinsonians with levodopa-induced motor complications, Mov Disord 18: 241-253.
12. Calon, F., Rajput, A.H., Hornykiewicz, O., Bedard, P.J. and Di Paolo, T. (2003 b) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease, Neurobiol Dis 14: 404-416.
13. Capria, A., Stocchi, F., Attanasio, A., Quatrana, M., Cannata, D. and Ruggieri, S. (1987) Unusual cardiovascular response to intravenous lisuride bolus. Possible drug-induced coronary angiospasm, Chest 91: 792-793.
14. Chan, P.L., Nutt, J.G. and Holford, N.H. (2005 a) Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease, J Pharmacokinet Pharmacodyn 32: 307-331.
15. Chan, P.L., Nutt, J.G. and Holford, N.H. (2005 b) Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease, J Pharmacokinet Pharmacodyn 32: 459-484.
16. Chase, T.N., Baronti, F., Fabbrini, G., Heuser, I.J., Juncos, J.L. and Mouradian, M.M. (1989) Rationale for continuous dopaminomimetic therapy of Parkinson's disease, Neurology 39: 7-10.
17. Chase, T.N. and Oh, J.D. (2000) Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications, Ann Neurol 47: S122-S129.
18. Colzi, A., Turner, K. and Lees, A.J. (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease, J Neurol Neurosurg Psychiatry 64: 573-576.
19. Constantinescu, R., Romer, M., McDermott, M.P., Kamp, C. and Kieburtz, K. (2007) Impact of pramipexole on the onset of levodopa-related dyskinesias, Mov Disord 22: 1317-1319.
20. de Gaspari, D., Siri, C., Landi, A., Cilia, R., Bonetti, A., Natuzzi, F. et al. (2006) Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus, J Neurol Neurosurg Psychiatry 77: 450-453.
21. Deleu, D., Ebinger, G. and Michotte, Y. (1991) Clinical and pharmacokinetic comparison of oral and duodenal delivery of levodopa / carbidopa in patients with Parkinson's disease with a fluctuating response to levodopa, Eur J Clin Pharmacol 41: 453-458.
22. Eggert, K., Schrader, C., Hahn, M., Stamelou, M., Russmann, A., Dengler, R. et al. (2008) Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications, Clin Neuropharmacol 31: 151-166.
23. Fahn, S., Oakes, D., Shoulson, I., Kieburtz, K., Rudolph, A., Lang, A. et al. (2004) Levodopa and the progression of Parkinson's disease, N Engl J Med 351: 2498-2508.
24. Ferreira, J.J. and Rascol, O. (2000) Prevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease, Curr Opin Neurol 13: 431-436.
25. Fowler, S.B. and Bergen, M. (1993) Continuous duodenal infusions of levodopa, J Neurosci Nurs 25: 317-320.
26. Giladi, N., Boroojerdi, B., Korczyn, A.D., Burn, D.J., Clarke, C.E. and Schapira, A.H. (2007) Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole, Mov Disord 22: 2398-2404.
27. Grace, A.A. and Bunney, B.S. (1984 a) The control of firing pattern in nigral dopamine neurons: burst firing, J Neurosci 4: 2877-2890.
28. Grace, A.A. and Bunney, B.S. (1984 b) The control of firing pattern in nigral dopamine neurons: single spike firing, J Neurosci 4: 2866-2876.
29. Haq, I.U., Lewitt, P.A. and Fernandez, H.H. (2007) Apomorphine therapy in Parkinson's disease: a review, Expert Opin Pharmacother 8: 2799-2809.
30. Hardoff, R., Sula, M., Tamir, A., Soil, A., Front, A., Badarna, S. et al. (2001) Gastric emptying time and gastric motility in patients with Parkinson's disease, Mov Disord 16: 1041-1047.
31. Hofmann, C., Penner, U., Dorow, R., Pertz, H.H., Jahnichen, S., Horowski, R. et al. (2006) Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis, Clin Neuropharmacol 29: 80-86.
32. Jankovic, J., Watts, R.L., Martin, W. and Boroojerdi, B. (2007) Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease, Arch Neurol 64: 676-682.
33. Johnston, T.H., Fox, S.H. and Brotchie, J.M. (2005) Advances in the delivery of treatments for Parkinson's disease, Expert Opin Drug Deliv 2: 1059-1073.
34. Jost, W.H., Buhmann, C., Fuchs, G., Greulich, W., Hummel, S., Korchounov, A. et al. (2008) Initial experience with ropinirole PR (prolonged release), J Neurol 255(Suppl. 5): 60-63.
35. Juncos, J.L., Mouradian, M.M., Fabbrini, G., Serrati, C. and Chase, T.N. (1987) Levodopa methyl ester treatment of Parkinson's disease, Neurology 37: 1242-1245.
36. Katzenschlager, R., Hughes, A., Evans, A., Manson, A.J., Hoffman, M., Swinn, L. et al. (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges, Mov Disord 20: 151-157.
37. Kurlan, R., Nutt, J.G., Woodward, W.R., Rothfield, K., Lichter, D., Miller, C. et al. (1988) Duodenal and gastric delivery of levodopa in parkinsonism, Ann Neurol 23: 589-595.
38. Kurth, M.C., Tetrud, J.W., Tanner, C.M., Irwin, I., Stebbins, G.T., Goetz, C.G. et al. (1993) Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa / carbidopa in Parkinson's disease patients with ‘on-off’ fluctuations, Neurology 43: 1698-1703.
39. Lewitt, P.A., Boroojerdi, B., MacMahon, D., Patton, J. and Jankovic, J. (2007 a) Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease, Clin Neuropharmacol 30: 256-265.
40. Lewitt, P.A., Lyons, K.E. and Pahwa, R. (2007 b) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study, Neurology 68: 1262-1267.
41. Marsden, C.D. and Parkes, J.D. (1977) Success and problems of long-term levodopa therapy in Parkinson's disease, Lancet 1: 345-349.
42. Nilsson, D., Nyholm, D. and Aquilonius, S.M. (2001) Duodenal levodopa infusion in Parkinson's disease-long-term experience, Acta Neurol Scand 104: 343-348.
43. Nutt, J.G. (2001) Motor fluctuations and dyskinesia in Parkinson's disease, Parkinsonism Relat Disord 8: 101-108.
44. Nutt, J.G., Obeso, J.A. and Stocchi, F. (2000) Continuous dopamine-receptor stimulation in advanced Parkinson's disease, Trends Neurosci 23: S109-S115.
45. Nyholm, D. and Aquilonius, S.M. (2004) Levodopa infusion therapy in Parkinson disease: state of the art in 2004, Clin Neuropharmacol 27: 245-256.
46. Nyholm, D., Lewander, T., Johansson, A., Lewitt, P.A., Lundqvist, C. and Aquilonius, S.M. (2008) Enteral levodopa / carbidopa infusion in advanced Parkinson disease: long-term exposure, Clin. Neuropharmacol 31: 63-73.
47. Nyholm, D., Nilsson Remahl, A.I., Dizdar, N., Constantinescu, R., Holmberg, B., Jansson, R. et al. (2005) Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease, Neurology 64: 216-223.
48. Obering, C.D., Chen, J.J. and Swope, D.M. (2006) Update on apomorphine for the rapid treatment of hypomobility (‘off’) episodes in Parkinson's disease, Pharmacotherapy 26: 840-852.
49. Obeso, J.A., Grandas, F., Herrero, M.T. and Horowski, R. (1994) The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease, Eur J Neurosci 6: 889-897.
50. Obeso, J.A., Rodriguez-Oroz, M., Marin, C., Alonso, F., Zamarbide, I., Lanciego, J.L. et al. (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits, Neurology 62: S17-S30.
51. Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., de Long, M.R. and Olanow, C.W. (2000 a) Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model, Ann Neurol 47: S22-S32.
52. Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., Lanciego, J.L., Artieda, J., Gonzalo, N. and Olanow, C.W. (2000 b) Pathophysiology of the basal ganglia in Parkinson's disease, Trends Neurosci 23: S8-19.
53. Olanow, C.W., Obeso, J.A. and Stocchi, F. (2006) Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications, Lancet Neurol 5: 677-687.
54. Olanow, W., Schapira, A.H. and Rascol, O. (2000) Continuous dopamine-receptor stimulation in early Parkinson's disease, Trends Neurosci 23: S117-S126.
55. Pahwa, R., Koller, W.C., Trosch, R.M. and Sherry, J.H. (2007 a) Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose, J Neurol Sci 258: 137-143.
56. Pahwa, R., Stacy, M.A., Factor, S.A., Lyons, K.E., Stocchi, F., Hersh, B.P. et al. (2007 b) Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease, Neurology 68: 1108-1115.
57. Pfeiffer, R.F. (2002) Potential of transdermal drug delivery in Parkinson's disease, Drugs Aging 19: 561-570.
58. Pham, D.Q. and Nogid, A. (2008) Rotigotine transdermal system for the treatment of Parkinson's disease, Clin Ther 30: 813-824.
59. Pietz, K., Hagell, P. and Odin, P. (1998) Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up, J Neurol Neurosurg Psychiatry 65: 709-716.
60. Poewe, W. and Wenning, G.K. (2000) Apomorphine: an underutilized therapy for Parkinson's disease, Mov Disord 15: 789-794.
61. Rascol, O., Brooks, D.J., Korczyn, A.D., de Deyn, P.P., Clarke, C.E. and Lang, A.E. (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group, N Engl J Med 342: 1484-1491.
62. Rascol, O., Brooks, D.J., Korczyn, A.D., de Deyn, P.P., Clarke, C.E., Lang, A.E. et al. (2006) Development of dyskinesias in a 5-year trial of ropinirole and L-dopa, Mov Disord 21: 1844-1850.
63. Rudzinska, M. and Szczudlik, A. (2007) [Apomorphine in off state-clinical experience], Neurol Neurochir Pol 41: S40-S48.
64. Ruggieri, S., Stocchi, F., Carta, A., Bragoni, M., Agostini, C., Barbato, L. et al. (1989) One year treatment with lisuride delivery pump in Parkinson's disease, Prog Neuropsychopharmacol Biol Psychiatry 13: 173-183.
65. Ruggieri, S., Stocchi, F., Carta, A., Bravi, D., Bragoni, M., Giorgi, L. et al. (1988) Comparison between L-dopa and lisuride intravenous infusions: a clinical study, Mov Disord 3: 313-319.
66. Schrag, A. and Quinn, N. (2000) Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study, Brain 123(Pt 11): 2297-2305.
67. Stocchi, F., Hersh, B.P., Scott, B.L., Nausieda, P.A. and Giorgi, L. (2008) Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study, Curr Med Res Opin 24: 2883-2895.
68. Stocchi, F., Ruggieri, S., Antonini, A., Baronti, F., Brughitta, G., Bellantuono, P. et al. (1988) Subcutaneous lisuride infusion in Parkinson's disease: clinical results using different modes of administration, J Neural Transm 27(Suppl. 27): 27-33.
69. Stocchi, F., Ruggieri, S., Carta, A., Ryatt, J., Quinn, N., Jenner, P. et al. (1992) Intravenous boluses and continuous infusions of L-dopa methyl ester in fluctuating patients with Parkinson's disease, Mov Disord 7: 249-256.
70. Stocchi, F., Ruggieri, S., Vacca, L. and Olanow, C.W. (2002) Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease, Brain 125: 2058-2066.
71. Stocchi, F., Vacca, L., Ruggieri, S. and Olanow, C.W. (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study, Arch Neurol 62: 905-910.
72. Suri, R.E. (2002) TD models of reward predictive responses in dopamine neurons, Neural Netw 15: 523-533.
73. Syed, N., Murphy, J., Zimmerman Jr T., Mark, M.H. and Sage, J.I. (1998) Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease, Mov Disord 13: 336-338.
74. Tompson, D.J. and Vearer, D. (2007) Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease, Clin Ther 29: 2654-2666.
75. Vaamonde, J., Luquin, M.R. and Obeso, J.A. (1991) Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients, Brain 114(Pt 1B): 601-617.
76. Watts, R.L., Jankovic, J., Waters, C., Rajput, A., Boroojerdi, B. and Rao, J. (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease, Neurology 68: 272-276.